Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”) ( Stock Code: 03692) was successfully listed on the Main Board of the Stock Exchange of Hong Kong Limited on14 June 2019.
Morgan Stanley and Citibank are the joint sponsors of this listing , and its global offering has attracted nine internationally renowned cornerstone investors, including Hillhouse Capital, Boyu Capital and GIC. The listing has been largely oversubscribed both in Hong Kong market (11 times) and the global market, finalized with the ceiling price HKD 14.26 of the offering price. Hansoh Pharma gained a positive start after opening, surged over 40% with its market value tops HKD 1100 billion, which made it the most valuable company in the medicine plate. Hansoh Pharma has undoubtedly becoming a star enterprise of the medicine plate HK stock market with its outstanding R&D ability, production, sales and management skills as well as profitability. Charles Li, CEO of the HKEx, attended the ceremony and extended his congratulations to Hansoh Pharma and to Zhong Huijuan, founding chief executive officer and chairman of the board.
Hansoh Pharma (including Jiangsu Hansoh Pharma Group co., ltd. and other subsidiaries in China) is one of the few R&D-driven Chinese pharmaceutical companies with an established leadership position in some of the largest and fastest-growing therapeutic areas in China with significant unmet clinical needs，which specialized in central nervous system diseases, oncology, anti-infectives, diabetes, gastrointestinal and cardiovascular therapeutic areas. Together, these six therapeutic areas accounted for 62.5% of the total sales revenue of its pharmaceuticals in China in 2018 and grew faster than the Chinese pharmaceutical industry as a whole, which grew at 8.1% on average from 2014 to 2018.
Currently, Hansoh Pharma had established world-class facilities and a manufacturing quality management system that comply with the cGMP requirements in China, the United States and Japan. Besides, through its strong R&D capabilities, Hansoh Pharma had yielded a diversified pipeline of Category 1.1 innovative drugs and potential first-to-market generic drug candidates in different stages of development spanning its key therapeutic areas. From 2019 to 2020, Hansoh Pharma targets to launch nearly 30 drug candidates including 15 drug candidates that it thinks have high growth potential, which comprise four candidates of Category 1.1 innovative drugs with NMEs and eight potential first-to-market generic drugs.
Li & Partners (Shenzhen) acted as the legal advisers to Hansoh Pharma with respect to PRC laws, has provided a full range of legal services for its reorganization and listing .
